Form 4: Artiva Biotherapeutics Director Alison Moore Granted 13,750 Stock Options

Artiva Biotherapeutics Director Alison Moore was granted 13,750 stock options with an exercise price of $1.61, vesting by June 2026.

Summary

• Alison Moore, a Director of Artiva Biotherapeutics, Inc. (ARTV), was granted 13,750 Director Stock Options.
• The transaction date for this grant was June 24, 2025.
• The exercise price for these stock options is $1.61 per share.
• The options are exercisable as of June 24, 2025, and have an expiration date of June 23, 2035.
• The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
• Following this transaction, Alison Moore beneficially owns 13,750 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholder value, indicating a positive incentive structure. This is a routine disclosure.

Positives

• The grant of 13,750 stock options to Director Alison Moore aligns her interests with long-term shareholder value.
• The options have a long expiration date of June 23, 2035, providing a sustained incentive for the director.

Future Outlook

The vesting schedule for the stock options, set for full vesting by June 24, 2026, or the 2026 annual stockholder meeting, indicates a future incentive for the director to contribute to the company's long-term performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries to attract and retain talent, and to align management and director incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, including those in the biopharmaceutical sector, to incentivize long-term value creation.
• The specific number of options (13,750) and exercise price ($1.61) would need comparison to peer companies of similar market capitalization and stage of development within the biotherapeutics industry to assess if it's within typical ranges for director compensation.

Stakeholder Impact

• Shareholders: Potential positive impact due to alignment of the director's interests with long-term company performance and value creation.

Next Steps

• The options will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

Key Dates

Recommendation

Keywords

Artiva Biotherapeutics, ARTV, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotherapeutics